Working Toward a Cure
Our researchers contribute to the South Carolina Central Cancer Registry.
Current Trials
Bladder Cancer
Cysview
Description
The purpose of the study is to gather more information on the current use of Blue Light Cystoscopy™ with Cysview® in urologists' practices. This trial is a registry study for patients with bladder cancer who undergo cystoscopy. Cysview is an FDA approved drug imaging agent that is absorbed by malignant cells causing them to appear pink under blue light thus making them easier to see.
Open to enrollment
Posted By: Dr. T. Brian Willard
Posted Date: 5/20/2022
Location: Lexington Urology
Breast Cancer
A012303 ShortStop-HER2: Shortened duration of adjuvant therapy in patient with early stage HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade.
Description
12 months versus 6 months of HER2-targeted medications for people with HER2+ breast cancer who had a pathologic complete response after chemotherapy plus trastuzumab.
Open to enrollment
Posted By: Dr. Steven Madden, Principal Investigator / Katharine Madden, Lead Coordinator
Location: Lexington Medical Cancer Center
EA1242 RxFINE-Low: A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS≤25
Description
The purpose of the study is to determine if patients with high anatomic risk but low genomic risk can safely forgo chemotherapy without increasing their chances of the cancer returning. It builds upon data from previous landmark trials (like TAILORx and RxPONDER) which proved that chemotherapy provides little to no benefit for most low-genomic-risk patients with early-stage disease.
Open to enrollment
Posted By: Dr. Steven Madden, Principal Investigator / Katharine Madden, Lead Coordinator
Location: Lexington Medical Cancer Center
WIDER
Description
A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2- early breast cancer.
The purpose of the study is to evaluate the effects of the study drug ribociclib given in combination with standard endocrine therapy ET for participants diagnosed with early breast cancer. In particular, this study aims to assess if ribociclib in combination with adjuvant ET (study treatment) can help reduce the risk for breast cancer to come back.
Posted By: Dr. Steven Madden
Location: Lexington Medical Cancer Center
S2212 SCARLET
Description
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
This phase III trial compares the effects of shorter chemotherapy-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Open to enrollment.
Posted By: Dr. Steven Madden
Posted Date: 8/28/2023
Location: Lexington Medical Cancer Center
A012103
Description
Pembrolizumab vs. observation in people with triple-negative breast cancer who had a pathologic complete response after chemotherapy plus pembrolizumab.
Open to enrollment.
Posted By: Dr. Steven Madden
Posted Date: 7/28/2023
Location: Lexington Medical Cancer Center
A212102
Description
Blinded Reference Set for Multicancer Early Detection Blood Tests. In this study, blood samples will be collected from patients with and without cancer to evaluate tests for early cancer detection.
Open to enrollment.
Posted By: Dr. James Wells
Posted Date: 6/23/2023
Location: Lexington Medical Cancer Center
Gastrointestinal Cancer
Head & Neck Cancer
Lung Cancer
SUNRAY-01 - A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pemetrexed and Platinum for the First-line treatment of Participants with KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer.
Description
This study is being done to see how safe an investigational drug is and how well it will work to help people with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (type of lung cancer caused by a gene alteration).
Open to enrollment.
Posted By: Dr. Scott Graupner, Principal Investigator / Selena Lollar, Lead Coordinator
Location: Lexington Medical Cancer Center
SUNRAY-02 - A Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer.
Description
The purpose of this research study is to learn more about olomorasib, a possible new investigational drug for the treatment of lung cancer. Investigational means that olomorasib is not approved by the United States Food and Drug Administration (FDA).
Open to enrollment.
Posted By: Dr. Scott Graupner, Principal Investigator / Selena Lollar, Lead Coordinator
Location: Lexington Medical Cancer Center
NRG-LU008
Description
NRG-LU008: Phase III Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer.
This study is testing the addition of high dose, targeted radiation to the usual treatment for locally advanced inoperable non-small cell lung cancer.
Open to enrollment.
Posted By: Dr. Quillin Davis
Posted Date: 7/29/2024
Location: Lexington Medical Cancer Center
Alchemist - A081801
Description
Testing the addition of a type of drug called immunotherapy to the usual chemotherapy treatment for non-small cell lung cancer
Open to enrollment
Posted By: Dr. James Wells
Posted Date: 11/23/2020
Location: Lexington Oncology
Prostate Cancer
S2312
Description
S2312 A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate-resistant Prostate Cancer (MCrPC), Stratified by Aggressive Variant Signature.
This trial is testing whether the addition of carboplatin chemotherapy to cabazitaxel chemotherapy with improve outcomes compared to cabazitaxel alone in people with castrate-resistant prostate cancer that has spread beyond the prostate to other parts of the body.
Open to enrollment.
Posted By: Dr. Scott Graupner
Posted Date: 4/29/2025
Location: Lexington Medical Cancer Center
